Kerntke Otto McGlone Wealth Management Group Sells 573 Shares of Pfizer Inc. (NYSE:PFE)

Kerntke Otto McGlone Wealth Management Group cut its stake in Pfizer Inc. (NYSE:PFE) by 7.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,387 shares of the biopharmaceutical company’s stock after selling 573 shares during the quarter. Kerntke Otto McGlone Wealth Management Group’s holdings in Pfizer were worth $213,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Briaud Financial Planning Inc bought a new position in Pfizer during the 3rd quarter valued at about $30,000. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the 4th quarter valued at $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.4 %

Shares of Pfizer stock traded up $0.11 on Friday, reaching $27.81. The stock had a trading volume of 60,568,852 shares, compared to its average volume of 41,900,304. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a 50 day moving average price of $26.88 and a 200 day moving average price of $28.21. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a P/E/G ratio of 1.18 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.23 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.36 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analysts Set New Price Targets

Several research firms have recently weighed in on PFE. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday. Finally, Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.